Staff Profile | Biomedical, Nutritional and Sport Sciences

Professor Steve Wedge

Prof of Stratified Cancer Med Discovery

Email: steve.wedge@ncl.ac.uk
Telephone: +44 (0) 191 208 4418

Publications

Lebraud H, Noble R, Phillips N, Hearn K, Castro J, Zhao Y, Newell DR, Lunec J, Wedge S, Heightman TD. A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition. Bioconjugate Chemistry 2018, 29(6), 2100-2106.
Miller DC, Martin MP, Adhikari S, Brennan A, Endicott JA, Golding BT, Hardcastle IR, Heptinstall A, Hobson S, Jennings C, Molyneux L, Ng Y, Wedge SR, Noble MEM, Cano C. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. Organic and Biomolecular Chemistry 2018, 16(11), 1843-1850.
Novo SM, Wedge SR, Stark LA. Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. Scientific Reports 2017, 7(1), 12020.
West MA, Roman A, Sayan E, Primrose JN, Wedge SR, Underwood TJ, Mirnezami AH. A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer. Critical Reviews in Oncology/Hematology 2017, 112, 80-102.
Tomassini S, Gentles L, Kirk C, Cross P, Thomas H, Wedge S, Curtin NJ, O'Donnell RL. An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer. In: BASO - The Association for Cancer Surgery Annual Scientific Conference and the NCRI Cancer Conference. 2017, Liverpool: Elsevier.
Jones D, Noble M, Wedge SR, Robson CN, Gaughan L. Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. Scientific Reports 2017, 7, 40957.
Coxon C, Anscombe E, Harnor S, Martin M, Carbain B, Golding B, Hardcastle I, Harlow L, Korolchuk S, Matheson C, Newell D, Noble M, Sivaprakasam M, Tudhope SJ, Turner D, Wang L, Wedge SR, Wong C, Griffin R, Endicott J, Cano C. Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry 2017, 60, 1746-1767.
Hallett ST, Pastok MW, Morgan RML, Wittner A, Blundell KLIM, Felletar I, Wedge SR, Prodromou C, Noble MEM, Pearl LH, Endicott JA. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Cell Reports 2017, 21(5), 1386-1398.
Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica 2017, 102(7), 1247-1257.
Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JPB, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR, NCRI CTRad Acad-Pharma Joint Worki. Clinical development of new drug-radiotherapy combinations. Nature Reviews. Clinical Oncology 2016, 13(10), 627-642.
Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ. Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. Cell Cycle 2016, 15(4), 506-518.
O'Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W, Cork D, Davies BR, Wedge SR, Robson CN, Gaughan L. Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget 2015, 6(28), 26029-26040.
Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble MEM, Wedge SR, Endicott JA, Griffin RJ. Identification and characterization of an irreversible inhibitor of CDK2. Chemistry & Biology 2015, 22(9), 1159-1164.
Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Molecular Cancer Therapeutics 2015, 14(1), 48-58.
Bell N, Blair H, Noble R, Price L, Wood K, Vormoor J, Bacon C, Rand V, Heidenreich O, Wedge S, Bomken S. Patient-derived xenograft and in vivo bioluminescent modelling of B-cell NHL. In: Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: Wiley-Blackwell.
Martin M, Anscombe E, Meschini E, Staunton D, Geitmann M, Danielson UH, Wang LZ, Vidal RM, Reuillon T, Golding BT, Newell DR, Wedge S, Noble MEM, Endicott JA, Griffin RJ. Identification and characterization of an irreversible inhibitor of CDK2. In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
Smith NR, Wedge SR, Pommier A, Barry ST. Mechanisms that influence tumour response to VEGF-pathway inhibitors. Biochemical Society Transactions 2014, 42(6), 1601-1607.
Tudhope S, Zhao Y, Wittner A, Wilmore E, Bertoli A, Adhikari S, Harnor SJ, Del Bello F, Piergentili A, Lunec J, Hardcastle IR, Griffin RJ, Golding BR, Cano C, Newell DR, Wedge SR. Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST. Tumor Stromal Phenotypes Define VEGF Sensitivity-Response. Clinical Cancer Research 2014, 20(19), 5141.
Bertoli A, Adhikari S, Harnor SJ, Zhao Y, Lunec J, Wedge SR, Tudhope S, Wittner A, Golding BT, Hardcastle IR, Cano C, Newell DR, Griffin RJ. Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction. In: 247th ACS National Meeting and Exposition. 2014, Dallas, TX, USA: American Chemical Society.
Kendrew J, Odedra R, Logie A, Taylor PJ, Pearsall S, Ogilvie DJ, Wedge SR, Jurgensmeier JM. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemotherapy and Pharmacology 2013, 71(4), 1021-1032.
Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TPJ, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RDO, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN. AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo. Molecular Cancer Therapeutics 2013, 12(9), 1715-1727.
Smith NR, Baker D, Farren M, Pommier AJC, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge S, Barry ST. Tumour-stromal architecture can define the intrinsic tumour response to VEGF-targeted therapy. Clinical Cancer Research 2013, n/a, n/a.
Keen H, Pichler B, Kukuk D, Duchamp O, Raguin O, Shannon A, Whalley N, Jacobs V, Bales J, Gingles G, Ricketts S-A, Wedge SR. An evaluation of 2-deoxy-2- [18F]fluoro-D-glucose and 3‟-Deoxy-3‟-[18F]-fluorothymidine uptake in human tumor xenograft models. Molecular Imaging and Biology 2012, 14(3), 355-365.
Farren M, Weston S, Brown H, Broadbent N, Powell S, Shaw R, Smith NR, Inglis R, Graham A, Ashton S, Wedge SR, Barry ST. Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies. Angiogenesis 2012, 15(4), 555-568.
Alferez DG, Goodlad RA, Odedra R, Sini P, Crafter C, Ryan AJ, Wedge SR, Wright NA, Anderson E, Wilkinson RW. Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia. International Journal of Oncology 2012, 41(4), 1475-1485.
Ataman OU, Sambrook SJ, Wilks C, Lloyd A, Taylor AE, Wedge SR. The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective. International Journal of Radiation Oncology - Biology - Physics 2012, 84(4), e447–e454.
Kendrew J, Eberlein CA, Blakey DC, Wedge SR, Foltz I, Kang P, Barry ST. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2 dependent angiogenesis without affecting ligand binding. Molecular Cancer Therapeutics 2011, 10(5), 770-783.
Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST. Assessing the Activity of Cediranib, a VEGFR-2/-3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family. Molecular Cancer Therapeutics 2011, 10(5), 861-873.
Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR, Stratford IJ. Inhibition of PARP-1 by Olaparib (AZD2281) Increasesthe Radiosensitivity of a Lung Tumor Xenograft. Molecular Cancer Therapeutics 2011, 10(10), 1949-1958.
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer 2010, 102(11), 1555-1577.
Brave SR, Eberlein C, Shibuya M, Wedge SR, Barry ST. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis 2010, 13(4), 337-347.
Bradley DP, Tessier JT, Lacey T, Scott M, Jürgensmeier JM, Odedra R, Mills J, Kilburn L, Wedge SR. Examining the acute effects of cediranib (RECENTINTM, AZD2171) treatment in tumor models: a dynamic contrast enhanced MRI (DCE-MRI) study using gadopentate. Magnetic Resonance Imaging 2009, 27(3), 377-384.
Harrison LRE, Ottley CJ, Pearson DG, Roche C, Wedge SR, Dolan ME, Newell DR, Tilby MJ. The kinase inhibitor O⁶-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Biochemical Pharmacology 2009, 77(10), 1586-1592.
Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ, Wedge SR. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY- 142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. Clinical Cancer Research 2009, 15(21), 6619-6629.
Curwen JO, Wedge SR. The use and refinement of rodent models in anti-cancer drug discovery: a review. Alternatives to Laboratory Animals 2009, 37(2), 173-180.
Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp radioligand, [18F]-AH111585, to determine changes in tumor vascularity after antitumor therapy. The Journal of Nuclear Medicine 2009, 50(1), 116-122.
Alferez D, Wilkinson RW, Watkins J, Poulsom R, Mandir N, Wedge SR, Pyrah IT, Smith NR, Jackson L, Ryan AJ, Goodlad RA. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice. Molecular Cancer Therapeutics 2008, 7(3), 590-598.
Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton JC, Kendrew J, Wedge SR. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR in Biomedicine 2008, 21(1), 42-52.
Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. British Journal of Radiology 2008, 81(Special issue 1), S21-S27.
Curwen JO, Musgrove HL, Kendrew J, Richmond GHP, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-A signaling induces hypertension: examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clinical Cancer Research 2008, 14(10), 3124-3131.
Foote KM, Mortlock AA, Heron NM, Jung FH, Hill GB, Pasquet G, Brady MC, Green S, Heaton SP, Kearney S, Keen NJ, Odedra R, Wedge SR, Wilkinson RW. Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity. Bioorganic & Medicinal Chemistry Letters 2008, 18(6), 1904-1909.
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Herttuala SY, Wedge SR, Jürgensmeier JM, Alitalo K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Research 2008, 68(12), 4754-4762.
Wedge SR, Jürgensmeier JM. VEGF receptor tyrosine kinase inhibitors for the treatment of cancer. In: Marmé, D and Fusenig, N, ed. Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy. New York: Springer, 2008, pp.395-423.
Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jürgensmeier JM, Wedge SR, Barry ST. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Molecular Cancer Therapeutics 2007, 6(8), 2198-2208.
Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, Bruns CJ. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anti-Cancer Drugs 2007, 18(5), 569-579.
Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical Cancer Research 2007, 13(12), 3682-3688.
Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Molecular Cancer Therapeutics 2007, 6(2), 599-606.
Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, DeSavi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. Journal of Medicinal Chemistry 2007, 50(9), 2213–2224.
Jung FH, Pasquet G, Lambert-vandeBrempt C, Lohmann JJ, Warin N, Renaud F, Germain H, DeSavi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Journal of Medicinal Chemistry 2006, 49(3), 955–970.
Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, Smith NR, Mandir N, Watkins AJ, Wilkinson RW. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 2006, 27(10), 2133-2139.
Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, Sone S. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncology Research 2006, 16(1), 15-26.
Ryan AJ, Wedge SR. ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. British Journal of Cancer 2005, 92(s1), S6-S13.
Nicholson B, Gulding K, Conway M, Wedge SR, Theodorescu D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clinical Cancer Research 2004, 10(24), 8728-8734.
Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Esser N. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004, 7(4), 347-354.
Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clinical Cancer Research 2004, 10(24), 8587-8593.
Checkley D, Tessier J, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC. Dynamic Contrast-Enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magnetic Resonance Imaging 2003, 21(5), 475-482.
Pradel C, Siauve N, Bruneteau G, Clement O, deBazelaire C, Frouin F, Wedge SR, Tessier JL, Robert PH, Frija G, Cuenod CA. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magnetic Resonance Imaging 2003, 21(8), 845-851.
Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. British Journal of Cancer 2003, 89(10), 1889-1895.
Gasmi A, Bourcier C, Aloui Z, Srairi N, Marchetti S, Gimond C, Wedge SR, Hennequin LF, Pouysségur J. Complete structure of an Increasing Capillary Permeability Protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via VEGF receptor signaling. Journal of Biological Chemistry 2002, 277(33), 29992-29998.
Hennequin LF, Stokes ESE, Thomas AP, Johnstone C, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO. Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry 2002, 45(6), 1300-1312.
Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 (“Iressa‟), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model. British Journal of Cancer 2002, 86(7), 1157-1161.
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Barnes C, Musgrove HL, Graham GA, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF, Hennequin LF. ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling and Growth of a Wide Range of Tumor Models Following Chronic Oral Administration. Cancer Research 2002, 62(16), 4645-4655.
Whittles CE, Pocock TM, Wedge SR, Kendrew J, Hennequin LF, Harper SJ, Bates DO. ZM323881, a novel inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) tyrosine kinase activity blocks VEGF-mediated increases in microvascular permeability in vivo. Microcirculation 2002, 9(6), 513-522.
Wedge SR, Ogilvie DJ. Inhibition of VEGF signal transduction. Identification of ZD4190. Advances in Experimental Medicine and Biology 2000, 476, 305-310.
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF. ZD4190: An orally active inhibitor of vascular endothelial growth factor signalling with broad-spectrum antitumor efficacy. Cancer Research 2000, 60(4), 970-975.
Hennequin LF, Thomas AP, Johnstone C, Stokes ESE, Plé PA, Lohmann JM, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-vanderBrempt C. Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry 1999, 42(26), 5369-5389.
Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, Lind MJ, Lee SM, Newell DR, Bleehen NM, Newlands ES, Calvert AH, Margison GP, Thatcher N. O⁶-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. British Journal of Cancer 1998, 78(9), 1199-1202.
Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Research 1998, 58(19), 4363-4367.
Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anti-Cancer Drugs 1997, 8(1), 92-97.
Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemotherapy and Pharmacology 1997, 40(3), 266-272.
Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Reviews 1997, 23(1), 35-61.
Wedge SR, Newlands ES. O^6-benzylguanine enhances the sensitivity of a glioma xenograft with low O⁶-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. British Journal of Cancer 1996, 73(9), 1049-1052.
Wedge SR, Porteous JK, Newlands ES. 3-Aminobenzamide and/or O⁶- benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment, in cell lines of varaible mismatch repair status and O⁶-alkylguanine-DNA alkyltransferase activity. British Journal of Cancer 1996, 74(7), 1030-1036.
Laohavinij S, Wedge S, Lind M, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor G, Thomas HD, Boddy AV, Newell DR, Calvert AH. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Investigational New Drugs 1996, 14(3), 325-335.
Wedge SR, Porteous JK, May BL, Newlands ES. Potentiation of temozolomide and BCNU cytotoxicity by O⁶-benzylguanine: a comparative study in vitro. British Journal of Cancer 1996, 73(4), 482-490.
Wedge SR, Laohavinij S, Taylor GA, Boddy AV, Calvert AH, Newell DR. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clinical Cancer Research 1995, 1(12), 1479-1486.
Wedge SR, Laohavinij S, Taylor GA, Newell DR. Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 1995, 663(2), 327-335.
Cassidy J, Newell DR, Wedge SR, Cummings J. Pharmacokinetics of high molecular weight agents. Cancer Surveys 1993, 17, 315-341.
Duncan R, Seymour LW, O'Hare KB, Flanagan PA, Wedge SR, Hume IC, Ulbrich K, Strohalm K, Subr V, Spreafico F, Grandi M, Ripamonti M, Farao M, Suarato A. Preclinical evaluation of polymer-bound doxorubicin. Journal of Controlled Release 1992, 19(1-3), 331-346.
Wedge SR, Duncan R, Kopeckova P. Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat. British Journal of Cancer 1991, 63(4), 546-549.
Seymour LW, Ulbrich K, Wedge SR, Hume IC, McCormick LA, Strohalm J, Duncan R. N-(2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA₂ mice. British Journal of Cancer 1991, 63(6), 859-866.